D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma

  • End date
    May 28, 2026
  • participants needed
  • sponsor
    Hospices Civils de Lyon
Updated on 9 June 2021
Olivier GLEHEN, Professor
Primary Contact
Service de Chirurgie Visc rale, CHU Estaing (0.0 mi away) Contact
+61 other location
ct scan
endoscopic ultrasound
serum bilirubin
neutrophil count
gastric carcinoma


A prospective, opened, multicentric, randomised, phase III trial with two arms:

  • Arm A: curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
  • Arm B: curative gastrectomy with D1-D2 lymph node dissection

Main objective: Compare overall 5-year survival rates in patients surgically treated for advanced gastric adenocarcinoma (T3, T4 and/or N+ and/or with positive peritoneal cytology), treated either with curative gastrectomy and adjuvant HIPEC, or with curative gastrectomy alone.

Condition Gastric Adenocarcinoma, stomach adenocarcinoma
Treatment HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin, Curative gastrectomy
Clinical Study IdentifierNCT01882933
SponsorHospices Civils de Lyon
Last Modified on9 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note